FDA
-
-
-
-
-
-
-
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
-
-
-
-
-
-
-
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
-
-
-
-
-
-
-
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
-
-
-
-
-
-
-
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November
-
-
-
-
-
-
-
Protara Therapeutics (TARA) names William Conkling as Chief Commercial Officer
-
-
-
-
-
-
-
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
-
-
-
-
-
-
-
Protara Therapeutics (TARA) Reports Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002
-
329,911 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

